D
셀비온
308430KOSDAQ의약품 제조업39.5 / 100
Reference Date: 2026-04-13
Financial Score4.0 / 40
News Sentiment12.5 / 25
Momentum13.0 / 20
Disclosure10.0 / 15
AI Analysis: the high debt ratio poses financial risk, ROE is below the industry average. Rose 12.3% over the past month, and news sentiment is neutral.
Company InformationBased on 2025 Annual Report
Business Overview
Cellon focuses on developing radiopharmaceuticals using Theranostics technology to realize precision medicine, with Lu-177-Pocuvotide as a key drug for prostate cancer treatment and diagnosis. The company completed phase II clinical trials in South Korea and secured final results by late 2025, leveraging its expertise in designing radiopharmaceuticals targeting various proteins through an open innovation strategy.
Number of Employees
56people
Average Salary
50.8M KRW
Score Calculation Basis
Detailed Financial Score
PER
—Industry Average 14.804.0Point
PBR
16.98Industry Average 1.040.0Point
16.3x industry avg (risky)
ROE
-28.93Industry Average 4.420.0Point
Well below industry avg
Debt Ratio
44.53Industry Average 11.980.0Point
3.7x industry avg (risky)
Trend 2024~20250.0 / 10 points
Revenue Growth Rate
0.0 / 3
Avg ▼15.1% (1-year basis)
Operating Profit Growth Rate
0.0 / 3
Avg ▼15.5% (1-year basis)
ROE Trend
0.0 / 4
Avg ROE -34.1% (improving, 2yr)
Detailed News Sentiment
1 totalPositive 0Neutral 0Negative 0
- Neutral
Detailed Momentum
52-week position6.0Point
52w upper range (60%)
Current 30,150Won52-week high 40,15052-week low 14,540
1-month return5.0Point
1m +12.29% (rising)
Volume trend2.0Point
Volume decreasing
Detailed Disclosure
5 totalPositive 0Neutral 5Negative 0
- Neutral정기주주총회결과2026-03-31
- Neutral주식매수선택권부여에관한신고2026-03-31
- Neutral사업보고서 (2025.12)2026-03-20
- Neutral신규시설투자등2026-03-20
- Neutral감사보고서제출2026-03-18